Human BTLA (B- and T-lymphocyte attenuator) ELISA KIT (HUFI05429)

Quantitative measurement of B- and T-lymphocyte attenuator (BTLA) underpins research into co-inhibitory signaling networks that govern peripheral lymphocyte responses. The Assay Genie microplate immunoassay captures soluble human BTLA using matched antibody pairs, supporting studies of immune checkpoint regulation across healthy and diseased tissue contexts.

BTLA belongs to the CD28 immunoglobulin superfamily alongside PD-1 and CTLA-4, engaging HVEM (herpes virus entry mediator) as its ligand to deliver inhibitory signals that restrain T cell and B cell activation. Researchers investigating tumor-infiltrating lymphocyte exhaustion, chronic viral immune dysfunction, and autoimmune dysregulation use BTLA quantification to characterize checkpoint molecule profiles in research cohorts.

Each kit provides reagents for 96 individual determinations and is configured for in vitro research use, fitting into workflows spanning small-scale biomarker pilot studies and larger translational investigations. Components include pre-coated plate wells, calibration standards, biotinylated detection antibody, streptavidin-HRP conjugate, and substrate solution. Standard laboratory ELISA equipment—a microplate reader capable of measuring absorbance—is required for data acquisition.

Practical applications include monitoring BTLA expression changes in response to therapeutic interventions, comparing checkpoint molecule levels between patient-derived research samples and healthy controls, and supporting preclinical development of novel immune modulators targeting the BTLA-HVEM axis.